International medical diagnostics company Panbio Limited today announced that it had developed two prototype immunoassays using their proprietary panDA Homogeneous Assay technology.
Panbios prototype panDA Homogeneous Assays are able to specifically and accurately detect and differentiate IgG antibodies induced by infection with Herpes Simplex Virus (HSV) 1 and HSV 2 in validated serum samples.
Commenting on the achievement of this milestone, Panbio Acting CEO, Dr Stuart Hazell said, This is clear evidence that the panDA Homogeneous Assay technology is capable of differentiating similar analytes with high specificity, which is an area where other homogeneous immunoassay platforms typically flounder. Successfully demonstrating that the key components of the system and the analyte interact specifically and generate a clear signal represents an important breakthrough.
The announcement marks the achievement of a key milestone in developing the panDA Homogeneous Immunoassay technology. We have achieved the first functional prototype assays based on Panbios proprietary panDA Homogeneous Assay technology within the timeframe previously indicated to the market, said Panbio Chairman, Maj Gen (Ret) Peter Arnison.
Key advances achieved in the development of the prototype panDA Homogenous Assays include:
Sensitive and specific detection of a type specific antibody, IgG, induced by specific infection with either HSV 1 or HSV 2, with little or no cross reactivity between analytes.
Performance data obtained using a true homogeneous immunoassay format. A serum sample is added to a master reagent mix, which if positive produces a colorimetric signal that may be detected shortly thereafter.
Results that are comparable with those obtained by testing with the market leading kits using the current ELISA technology.
Generation of performance data by in-house testing of a panel of 150 samples.
The assay system
Contact: Dr Stuart Hazell